Recent tau-targeted clinical strategies for the treatment of Alzheimer's disease
- Recent tau-targeted clinical strategies for the treatment of Alzheimer's disease
- 배애님; 임상민; 이하은; 임다미; 이재열
- Issue Date
- FUTURE MEDICINAL CHEMISTRY
- VOL 11, NO 15-1848
- Recently terminated Phase III clinical trials of Aducanumab and Crenezumab have led researchers to further question the amyloid hypothesis for the onset of Alzheimer's disease (AD). These antibodies once had been considered as one of the most promising agents to be approved for AD. Due to the failure of clinical trials of these anti-amyloid β antibodies along with the unsuccessful studies of BACE1 inhibitors such as Lanabecestat and Verubecestat, people increasingly believe that modulation of amyloid β alone might not be enough to improve memory and cognitive function of AD patients. Many people postulate that clinical trials have failed because of the late administration of candidate drugs based on PET studies suggesting that amyloid β plaques are accumulated decades before clinical symptoms are manifested . Nevertheless, it became apparent that the amyloid hypothesis might explain only part of the complex pathologies of Alzheimer's diseases . The rapidly aging global population urgently necessitates development of disease modifying therapies for AD, thus scientists propose that it is ‘time to cast a wider net’  and to search for alternative promising targets in addition to amyloid β.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.